Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF EUROPE NATURAL KILLER (NK) CELL THERAPEUTICS MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATION
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 KEY TAKEAWAYS
2.2 ARRIVING AT THE EUROPE NATURAL KILLER (NK) CELL THERAPEUTICS MARKET SIZE
2.2.1 VENDOR POSITIONING GRID
2.2.2 TECHNOLOGY LIFE LINE CURVE
2.2.3 TRIPOD DATA VALIDATION MODEL
2.2.4 MARKET GUIDE
2.2.5 MULTIVARIATE MODELLING
2.2.6 TOP TO BOTTOM ANALYSIS
2.2.7 CHALLENGE MATRIX
2.2.8 APPLICATION COVERAGE GRID
2.2.9 STANDARDS OF MEASUREMENT
2.2.10 VENDOR SHARE ANALYSIS
2.2.11 EPIDEMIOLOGY
2.2.12 DATA POINTS FROM KEY PRIMARY INTERVIEWS
2.2.13 DATA POINTS FROM KEY SECONDARY DATABASES
2.3 EUROPE NATURAL KILLER (NK) CELL THERAPEUTICS MARKET: RESEARCH SNAPSHOT
2.4 ASSUMPTIONS
3 MARKET OVERVIEW
3.1 DRIVERS
3.2 RESTRAINTS
3.3 OPPORTUNITIES
3.4 CHALLENGES
4 EXECUTIVE SUMMARY
5 PREMIUM INSIGHTS
5.1 PESTEL ANALYSIS
5.2 PORTER’S FIVE FORCES MODEL
6 INDUSTRY INSIGHTS
6.1 PATENT ANALYSIS
6.1.1 PATENT LANDSCAPE
6.1.2 USPTO NUMBER
6.1.3 PATENT EXPIRY
6.1.4 EPIO NUMBER
6.1.5 PATENT STRENGTH AND QUALITY
6.1.6 PATENT CLAIMS
6.1.7 PATENT CITATIONS
6.1.8 PATENT LITIGATION AND LICENSING
6.1.9 FILE OF PATENT
6.1.10 PATENT RECEIVED CONTRIES
6.1.11 TECHNOLOGY BACKGROUND
6.2 DRUG TREATMENT RATE BY MATURED MARKETS
6.3 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES
6.4 PATIENT FLOW DIAGRAM
6.5 KEY PRICING STRATEGIES
6.6 KEY PATIENT ENROLLMENT STRATEGIES
6.7 INTERVIEWS WITH SPECIALIST
6.8 OTHER KOL SNAPSHOTS
7 EPIDEMIOLOGY
7.1 INCIDENCE OF ALL BY GENDER
7.2 TREATMENT RATE
7.3 MORTALITY RATE
7.4 DRUG ADHERENCE AND THERAPY SWITCH MODEL
7.5 PATIENT TREATMENT SUCCESS RATES
8 MERGERS AND ACQUISITION
8.1 LICENSING
8.2 COMMERCIALIZATION AGREEMENTS
9 REGULATORY FRAMEWORK
9.1 REGULATORY APPROVAL PROCESS
9.2 GEOGRAPHIES’ EASE OF REGULATORY APPROVAL
9.3 REGULATORY APPROVAL PATHWAYS
9.4 LICENSING AND REGISTRATION
9.5 POST-MARKETING SURVEILLANCE
9.6 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES
10 PIPELINE ANALYSIS
10.1 CLINICAL TRIALS AND PHASE ANALYSIS
10.2 DRUG THERAPY PIPELINE
10.3 PHASE III CANDIDATES
10.4 PHASE II CANDIDATES
10.5 PHASE I CANDIDATES
10.6 OTHERS (PRE-CLINICAL AND RESEARCH)
TABLE 1 EUROPE CLINICAL TRIAL MARKET FOR NATURAL KILLER (NK) CELL THERAPEUTICS MARKET
Company Name Therapeutic Area
XX XX
XX XX
XX XX
XX XX
XX XX
XX XX
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
TABLE 2 DISTRIBUTION OF PRODUCTS AND PROJECTS BY PHASE
Phase Number of Projects
Preclinical/Research Projects XX
Clinical Development XX
Phase I XX
Phase II XX
Phase III XX
U.S. Filed/Approved But Not Yet Marketed XX
Total XX
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
TABLE 3 DISTRIBUTION OF PROJECTS BY THERAPEUTIC AREA AND PHASE
Therapeutic Area Preclinical/ Research Project
XX XX
XX XX
XX XX
XX XX
XX XX
Total Projects XX
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
TABLE 4 DISTRIBUTION OF PROJECTS BY SCIENTIFIC APPROACH AND PHASE
Technology Preclinical/ Research Project
XX XX
XX XX
XX XX
XX XX
XX XX
Total Projects XX
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
FIGURE 1 TOP ENTITIES BASED ON R&D GLANCE FOR XX
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
11 MARKETED DRUG ANALYSIS
11.1 DRUG
11.1.1 BRAND NAME
11.1.2 GENERICS NAME
11.2 THERAPEUTIC INDICTION
11.3 PHARMACOLOGICAL CLASS OF THE DRUG
11.4 DRUG PRIMARY INDICATION
11.5 MARKET STATUS
11.6 MEDICATION TYPE
11.7 DRUG DOSAGES FORM
11.8 DOSAGES AVAILABILITY
11.9 DRUG ROUTE OF ADMINISTRATION
11.1 DOSING FREQUENCY
11.11 DRUG INSIGHT
11.12 AN OVERVIEW OF THE DRUG DEVELOPMENT ACTIVITIES SUCH AS REGULATORY MILSTONE, SAFETY DATA AND EFFICACY DATA, MARKET EXCLUSIVITY DATA.
11.12.1 FORECAST MARKET OUTLOOK
11.12.2 CROSS COMPETITION
11.12.3 THERAPEUTIC PORTFOLIO
11.12.4 CURRENT DEVELOPMENT SCENARIO
12 MARKET ACCESS
12.1 10-YEAR MARKET FORECAST
12.2 CLINICAL TRIAL RECENT UPDATES
12.3 ANNUAL NEW FDA APPROVED DRUGS
12.4 DRUGS MANUFACTURER AND DEALS
12.5 MAJOR DRUG UPTAKE
12.6 CURRENT TREATMENT PRACTICES
12.7 IMPACT OF UPCOMING THERAPY
13 R & D ANALYSIS
13.1 COMPARATIVE ANALYSIS
13.2 DRUG DEVELOPMENTAL LANDSCAPE
13.3 IN-DEPTH INSIGHTS ON REGULATORY MILESTONES
13.4 THERAPEUTIC ASSESSMENT
13.5 ASSET-BASED COLLABORATIONS AND PARTNERSHIPS
14 MARKET OVERVIEW
14.1 DRIVERS
14.2 RESTRAINTS
14.3 OPPORTUNITIES
14.4 CHALLENGES
15 EUROPE NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY SOURCE
15.1 OVERVIEW
15.2 AUTOLOGOUS CELLS
15.2.1 NATURAL KILLER (NK) CELL
15.2.2 CAR (CHIMERIC ANTIGEN RECEPTOR) NK CELLS
15.3 ALLOGENIC CELLS
15.3.1 NATURAL KILLER (NK) CELL
15.3.2 CAR (CHIMERIC ANTIGEN RECEPTOR) NK CELLS
16 EUROPE NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY TYPE
16.1 OVERVIEW
16.2 NATURAL KILLER (NK) CELL
16.2.1 BY ORIGIN
16.2.1.1. DONOR-DERIVED NK
16.2.1.1.1. UMBILICAL CORD
16.2.1.1.2. PLACENTA
16.2.1.2. IPSC-NK CELLS
16.2.1.3. CYTOKINE-INDUCED
16.2.1.4. OTHERS
16.2.1.4.1. PB-NK CELLS
16.2.1.4.2. UB-NK CELLS
16.2.1.4.3. NK92 CELLS
16.2.2 BY THERAPEUTICS
16.2.2.1. NK CELL THERAPIES
16.2.2.2. NK CELL DIRECTED ANTIBODIES
16.2.2.3. OTHERS
16.2.3 BY APPROACHES
16.2.3.1. BISPECIFIC ANTIBODIES
16.2.3.2. ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY (ADCC)
16.2.3.3. CELL-AND-GENE-THERAPY WITH NK CELLS
16.2.3.4. OTHERS
16.3 CAR (CHIMERIC ANTIGEN RECEPTOR) NK CELLS
16.3.1 CAR-NK CELLS
16.3.1.1. BY SOURCE
16.3.1.1.1. AUTOLOGOUS CAR-NK CELLS
16.3.1.1.2. ALLOGENEIC CAR-NK CELLS
16.3.1.2. BY NK CELLS ENGINEERED
16.3.1.2.1. PERIPHERAL BLOOD
16.3.1.2.2. UMBILICAL CORD BLOOD
16.3.1.2.3. CELL LINES (NK-92)
16.3.1.2.4. IPSC-DERIVED CAR NK
16.3.1.3. BY STRUCTURE
16.3.1.3.1. FIRST-GENERATION
16.3.1.3.2. SECOND-GENERATION
16.3.1.3.3. THIRD-GENERATION
16.3.1.4. BY BRAND (PIPELINE)
16.3.1.4.1. AB-205
16.3.1.4.2. AB-201
16.3.1.4.3. TAK-007
16.3.1.4.4. CYTO NK-102
16.3.1.4.5. OTHERS
17 EUROPE NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY THERAPEUTICS
17.1 OVERVIEW
17.2 FIRST-GENERATION
17.3 SECOND-GENERATION
17.4 THIRD-GENERATION
17.5 FOURTH-GENERATION
18 EUROPE NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY AGE GROUP
18.1 OVERVIEW
18.2 PEDIATRIC
18.3 ADULTS
18.4 GERIATRIC
19 EUROPE NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY GENDER
19.1 OVERVIEW
19.2 MALE
19.2.1 CHILDREN (0-15)
19.2.2 ADULT (16- 64)
19.2.3 SENIORS (65 AND ABOVE)
19.3 FEMALE
19.3.1 CHILDREN (0-15)
19.3.2 ADULT (16- 64)
19.3.3 SENIORS (65 AND ABOVE)
20 EUROPE NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION
20.1 OVERVIEW
20.2 FOLLICULAR LYMPHOMA
20.3 DIFFUSE LARGE B-CELL LYMPHOMA
20.4 ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)
20.5 MANTLE CELL LYMPHOMA
20.6 MULTIPLE MYELOMA
20.7 HEMATOLOGIC MALIGNANCIES
20.7.1 LEUKEMIA
20.7.2 LYMPHOMA
20.7.3 MYELOMA
20.7.4 OTHERS
20.8 LUNG CANCER
20.9 BREAST CANCER
20.1 GASTRIC CANCER
20.11 PANCREATIC CANCER
20.12 CHRONIC LYMPHOCYTIC LEUKEMIA
20.13 OTHERS
21 EUROPE NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY END USER
21.1 OVERVIEW
21.2 HOSPITALS
21.2.1 PUBLIC
21.2.2 PRIVATE
21.3 SPECIALTY CLINICS
21.4 ONCOLOGY CENTRES
21.5 RESEARCH & ACADEMIC INSTITUTES
21.6 OTHERS
22 EUROPE NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL
22.1 OVERVIEW
22.2 DIRECT TENDER
22.3 RETAIL SALES
22.4 OTHERS
23 EUROPE NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, COMPANY LANDSCAPE
23.1 COMPANY SHARE ANALYSIS: EUROPE
23.2 MERGERS & ACQUISITIONS
23.3 NEW PRODUCT DEVELOPMENT & APPROVALS
23.4 EXPANSIONS
23.5 REGULATORY CHANGES
23.6 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
24 EUROPE NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY REGION
EUROPE NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, (EUROPE SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
24.1 EUROPE
24.1.1 GERMANY
24.1.2 FRANCE
24.1.3 U.K.
24.1.4 HUNGARY
24.1.5 LITHUANIA
24.1.6 AUSTRIA
24.1.7 IRELAND
24.1.8 NORWAY
24.1.9 POLAND
24.1.10 ITALY
24.1.11 SPAIN
24.1.12 RUSSIA
24.1.13 TURKEY
24.1.14 NETHERLANDS
24.1.15 SWITZERLAND
24.1.16 REST OF EUROPE
24.2 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES
25 EUROPE NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, SWOT AND DBMR ANALYSIS
26 EUROPE NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, COMPANY PROFILE
(SWOT AND DBMR ANALYSIS OF TOP 5 COMPANIES WILL BE PROVIDED)
26.1 SHORELINE BIOSCIENCES
26.1.1 COMPANY OVERVIEW
26.1.2 REVENUE ANALYSIS
26.1.3 GEOGRAPHIC PRESENCE
26.1.4 RECENT DEVELOPMENTS
26.2 HEBECELL CORP + ANKARYS THERAPEUTICS + APPLIED STEMCELL
26.2.1 COMPANY OVERVIEW
26.2.2 REVENUE ANALYSIS
26.2.3 GEOGRAPHIC PRESENCE
26.2.4 PRODUCT PORTFOLIO
26.2.5 RECENT DEVELOPMENTS
26.3 CYTOVIA THERAPEUTICS
26.3.1 COMPANY OVERVIEW
26.3.2 REVENUE ANALYSIS
26.3.3 GEOGRAPHIC PRESENCE
26.3.4 RECENT DEVELOPMENTS
26.4 NKARTA, INC.
26.4.1 COMPANY OVERVIEW
26.4.2 REVENUE ANALYSIS
26.4.3 GEOGRAPHIC PRESENCE
26.4.4 PRODUCT PORTFOLIO
26.4.5 RECENT DEVELOPMENTS
26.5 IMMUNITYBIO, INC. + NANTKWEST
26.5.1 COMPANY OVERVIEW
26.5.2 REVENUE ANALYSIS
26.5.3 GEOGRAPHIC PRESENCE
26.5.4 PRODUCT PORTFOLIO
26.5.5 RECENT DEVELOPMENTS
26.6 TAKEDA PHARMACEUTICAL COMPANY LIMITED
26.6.1 COMPANY OVERVIEW
26.6.2 REVENUE ANALYSIS
26.6.3 GEOGRAPHIC PRESENCE
26.6.4 PRODUCT PORTFOLIO
26.6.5 RECENT DEVELOPMENTS
26.7 ABIVAX
26.7.1 COMPANY OVERVIEW
26.7.2 REVENUE ANALYSIS
26.7.3 GEOGRAPHIC PRESENCE
26.7.4 PRODUCT PORTFOLIO
26.7.5 RECENT DEVELOPMENTS
26.8 AFFIMED N.V. + ARTIVA BIOTHERAPEUTICS INC.
26.8.1 COMPANY OVERVIEW
26.8.2 REVENUE ANALYSIS
26.8.3 GEOGRAPHIC PRESENCE
26.8.4 PRODUCT PORTFOLIO
26.8.5 RECENT DEVELOPMENTS
26.9 FORTRESS BIOTECH, INC.
26.9.1 COMPANY OVERVIEW
26.9.2 REVENUE ANALYSIS
26.9.3 GEOGRAPHIC PRESENCE
26.9.4 PRODUCT PORTFOLIO
26.9.5 RECENT DEVELOPMENTS
26.1 CANTARGIA AB
26.10.1 COMPANY OVERVIEW
26.10.2 REVENUE ANALYSIS
26.10.3 GEOGRAPHIC PRESENCE
26.10.4 PRODUCT PORTFOLIO
26.10.5 RECENT DEVELOPMENTS
26.11 FATE THERAPEUTICS
26.11.1 COMPANY OVERVIEW
26.11.2 REVENUE ANALYSIS
26.11.3 GEOGRAPHIC PRESENCE
26.11.4 PRODUCT PORTFOLIO
26.11.5 RECENT DEVELOPMENTS
26.12 GLYCOSTEM
26.12.1 COMPANY OVERVIEW
26.12.2 REVENUE ANALYSIS
26.12.3 GEOGRAPHIC PRESENCE
26.12.4 PRODUCT PORTFOLIO
26.12.5 RECENT DEVELOPMENTS
26.13 SORRENTO THERAPEUTICS, INC.
26.13.1 COMPANY OVERVIEW
26.13.2 REVENUE ANALYSIS
26.13.3 GEOGRAPHIC PRESENCE
26.13.4 PRODUCT PORTFOLIO
26.13.5 RECENT DEVELOPMENTS
26.14 ALL LIFE ADVANCED IMMUNOLOGY
26.14.1 COMPANY OVERVIEW
26.14.2 REVENUE ANALYSIS
26.14.3 GEOGRAPHIC PRESENCE
26.14.4 PRODUCT PORTFOLIO
26.14.5 RECENT DEVELOPMENTS
26.15 EXACIS BIOTHERAPEUTICS, INC.
26.15.1 COMPANY OVERVIEW
26.15.2 REVENUE ANALYSIS
26.15.3 GEOGRAPHIC PRESENCE
26.15.4 PRODUCT PORTFOLIO
26.15.5 RECENT DEVELOPMENTS
26.16 NKMAX CO., LTD.
26.16.1 COMPANY OVERVIEW
26.16.2 REVENUE ANALYSIS
26.16.3 GEOGRAPHIC PRESENCE
26.16.4 PRODUCT PORTFOLIO
26.16.5 RECENT DEVELOPMENTS
26.17 NEKTAR
26.17.1 COMPANY OVERVIEW
26.17.2 REVENUE ANALYSIS
26.17.3 GEOGRAPHIC PRESENCE
26.17.4 PRODUCT PORTFOLIO
26.17.5 RECENT DEVELOPMENTS
26.18 GAMIDA CELL LTD
26.18.1 COMPANY OVERVIEW
26.18.2 REVENUE ANALYSIS
26.18.3 GEOGRAPHIC PRESENCE
26.18.4 PRODUCT PORTFOLIO
26.18.5 RECENT DEVELOPMENTS
26.19 MULTIMMUNE GMBH
26.19.1 COMPANY OVERVIEW
26.19.2 REVENUE ANALYSIS
26.19.3 GEOGRAPHIC PRESENCE
26.19.4 PRODUCT PORTFOLIO
26.19.5 RECENT DEVELOPMENTS
26.2 XNK THERAPEUTICS
26.20.1 COMPANY OVERVIEW
26.20.2 REVENUE ANALYSIS
26.20.3 GEOGRAPHIC PRESENCE
26.20.4 PRODUCT PORTFOLIO
26.20.5 RECENT DEVELOPMENTS
NOTE: THE COMPANIES PROFILED IS NOT EXHAUSTIVE LIST AND IS AS PER OUR PREVIOUS CLIENT REQUIREMENT. WE PROFILE MORE THAN 100 COMPANIES IN OUR STUDY AND HENCE THE LIST OF COMPANIES CAN BE MODIFIED OR REPLACED ON REQUEST
27 RELATED REPORTS
28 CONCLUSION
29 QUESTIONNAIRE
30 ABOUT DATA BRIDGE MARKET RESEARCH
